$4.69 Billion is the total value of RA Capital Management's 81 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLBS | Exit | CALADRIUS BIOSCIENCES | $0 | – | -752,500 | -100.0% | -0.01% | – |
| AVRO | Exit | AVROBIO INC | $0 | – | -559,600 | -100.0% | -0.01% | – |
| OLMA | Exit | OLEMA PHARMACEUTICALS INC | $0 | – | -233,793 | -100.0% | -0.02% | – |
| ORTX | Exit | ORCHARD THERAPEUTICS PLCads | $0 | – | -3,040,885 | -100.0% | -0.05% | – |
| LRMR | Exit | LARIMAR THERAPEUTICS INC | $0 | – | -1,031,482 | -100.0% | -0.05% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -1,726,019 | -100.0% | -0.06% | – |
| Exit | ASTRIA THERAPEUTICS INC | $0 | – | -760,857 | -100.0% | -0.06% | – | |
| BCAB | Exit | BIOATLA INC | $0 | – | -1,031,805 | -100.0% | -0.08% | – |
| TERN | Exit | TERNS PHARMACEUTICALS INC | $0 | – | -1,261,435 | -100.0% | -0.08% | – |
| FLDM | Exit | STANDARD BIOTOOLS INC | $0 | – | -1,987,589 | -100.0% | -0.08% | – |
| Exit | XILIO THERAPEUTICS INC | $0 | – | -1,649,711 | -100.0% | -0.13% | – | |
| BMEA | Exit | BIOMEA FUSION INC | $0 | – | -500,000 | -100.0% | -0.16% | – |
| IPSC | Exit | CENTURY THERAPEUTICS INC | $0 | – | -756,821 | -100.0% | -0.17% | – |
| Exit | LIANBIOsponsored ads | $0 | – | -4,622,574 | -100.0% | -0.27% | – | |
| OTIC | Exit | OTONOMY INC | $0 | – | -5,600,000 | -100.0% | -0.31% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -476,380 | -100.0% | -0.51% | – |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -2,805,045 | -100.0% | -0.51% | – |
| NTRA | Exit | NATERA INC | $0 | – | -1,310,289 | -100.0% | -1.24% | – |
| PNT | Exit | POINT BIOPHARMA GLOBAL INC | $0 | – | -9,003,018 | -100.0% | -1.64% | – |
| VERU | Exit | VERU INC | $0 | – | -7,900,000 | -100.0% | -2.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
About RA Capital Management
RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.
The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.
RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.
Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.
Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ASCENDIS PHARMA A/S - ADR | 35 | Q3 2023 | 25.5% |
| WAVE LIFE SCIENCES PTE LTD | 32 | Q3 2023 | 26.3% |
| TG THERAPEUTICS INC | 30 | Q4 2021 | 6.3% |
| ZOGENIX INC | 26 | Q4 2021 | 9.5% |
| BIOCRYST PHARMACEUTICALS | 23 | Q1 2019 | 9.2% |
| DICERNA PHARMACEUTICALS INC | 23 | Q3 2019 | 5.8% |
| RHYTHM PHARMACEUTICALS INC | 22 | Q3 2023 | 4.4% |
| ACHILLION PHARMACEUTICALS INC | 19 | Q4 2017 | 17.2% |
| KALA PHARMACEUTICALS INC | 19 | Q1 2022 | 4.4% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 6.8% |
View RA Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | September 22, 2023 | 6,940,000 | 6.2% |
| BELLUS Health Inc.Sold out | August 14, 2023 | 0 | 0.0% |
| Kinnate Biopharma Inc.Sold out | August 14, 2023 | 0 | 0.0% |
| Vor Biopharma Inc. | August 11, 2023 | 22,780,343 | 33.7% |
| DICE Therapeutics, Inc.Sold out | August 09, 2023 | 0 | 0.0% |
| Acumen Pharmaceuticals, Inc. | July 25, 2023 | 14,981,618 | 25.9% |
| Talaris Therapeutics, Inc. | July 06, 2023 | 2,333,175 | 5.5% |
| Aerovate Therapeutics, Inc. | June 27, 2023 | 8,293,148 | 30.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | June 12, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp VSold out | May 15, 2023 | 0 | 0.0% |
View RA Capital Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-15 |
| 4 | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-12 |
| SC 13G | 2024-04-12 |
| SC 13D/A | 2024-04-11 |
| SC 13G | 2024-04-11 |
| 4 | 2024-04-04 |
| SC 13G | 2024-04-04 |
| SC 13G | 2024-04-01 |
View RA Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.